Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation

To the best of our knowledge, non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants, have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), affected by malignant disease. However, their use in patients with cancer is increasing, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Undas, Anetta, Drabik, Leszek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141434/
https://www.ncbi.nlm.nih.gov/pubmed/31911561
http://dx.doi.org/10.14744/AnatolJCardiol.2019.30766
Descripción
Sumario:To the best of our knowledge, non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants, have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), affected by malignant disease. However, their use in patients with cancer is increasing, while real-life evidence for their effectiveness and safety in this vulnerable subset of patients is growing. The challenges of the use of NOACs in cancer patients with AF and current expert opinion on this subject have been summarized in this review article.

Ejemplares similares